CORYFIN SCIR 200ML POLICY

CORYFIN MUCOLITICAL 250 MG/5 ML SCIROPPOSE

active ingredients

5 ml syrup contains 250 mg of excipient carbocysteine with known effects: methyl parahydroxybenzoate, sucrose, sodium phosphate bibasic dodecaidrate and sodium hydroxide. For the full list of excipients, see paragraph 6.1.

Excellent

Sodium phosphate bibasic; methyl parahydroxybenzoate; sucrose; fruit flavouring; hydroxide sodium; purified water.

Therapeutic indications

Mucolitic, fluidizing in the acute and chronic affections of the respiratory system.

Contraindications

• Hypersensitivity to the active ingredient or any of the excipients listed in paragraph 6.1. • Peptic ulcer (i.e. digestive tract) in active phase. • Contraindicated in pregnancy and nursing (see paragraph 4.6). • The drug is contraindicated in children under 2 years of age.

Population

Population Adults: 1 tablespoon 3 times a day. Pediatric population Children from 2 to 5 years: 1 teaspoon (5 ml) 2 times a day. Children from 5 to 10 years: 1 tablespoon (15 ml) 2 times a day.

Conservation

Store at a temperature below 25°C.

Warnings

No special precautions are indicated for the use of CORYFIN MUCOLITICAL. Mucolitics may induce bronchial obstruction in children under 2 years of age. In fact the drainage capacity of the bronchial mucus is limited in this age range, due to the physiological characteristics of the respiratory tract. They must not be used in children under 2 years of age (see paragraph 4.3). CORYFIN MUCOLITICAL: • methyl parahydroxybenzoate: may cause allergic reactions (also delayed). • sucrose: patients with rare hereditary problems of fructose intolerance, glucose–galactose mal absorption, or isomaltase sucrasis failure, should not take this medicine. This medicine contains 6.3 g per dose (one spoon) of sucrose. To consider in people with diabetes mellitus. • sodium: this medicine contains 4.8 mmol (or 110.55 mg) of sodium per dose (one spoon). To be considered in people with reduced kidney function or following a low sodium diet.

Interactions

Pharmacological interactions are not described CORYFIN MUCOLITICAL.

Effects

Dizziness and digestive phenomena such as gastralgia, nausea and diarrhea may occur. In these cases it is necessary to reduce posology or stop therapy. In addition, allergic rashes and anaphylactic reactions, fixed erythema may occur. In such cases stop treatment and consult your doctor to establish suitable therapy. Bronchial obstruction, with unknown frequency. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions occurring after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at: www.agenziafarmaco.gov.it/it/responsabili.

Overdosing

Symptoms due to overdose include: headaches, nausea, diarrhea, gastralgia. In the case of overdose cause vomiting and possibly practice gastric lavender.

Although the active ingredient is neither teratogenic nor mutagenic and has not shown any adverse effects on the reproductive function in the animal, data on its use in human pregnancy are not available. Therefore the use of the medicinal product is contraindicated in pregnancy. Since no data on the passage of carboxysteine in breast milk are available, the use of the medicinal product is contraindicated during feeding.

Source: Farmadati